Adlai Nortye (ANL) Competitors $2.20 -0.10 (-4.35%) (As of 04:12 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ANL vs. AQST, ETON, SLRN, BTMD, VYGR, CGC, TRVI, SNDL, PROC, and CRVSShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Aquestive Therapeutics (AQST), Eton Pharmaceuticals (ETON), Acelyrin (SLRN), biote (BTMD), Voyager Therapeutics (VYGR), Canopy Growth (CGC), Trevi Therapeutics (TRVI), SNDL (SNDL), Procaps Group (PROC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Aquestive Therapeutics Eton Pharmaceuticals Acelyrin biote Voyager Therapeutics Canopy Growth Trevi Therapeutics SNDL Procaps Group Corvus Pharmaceuticals Aquestive Therapeutics (NASDAQ:AQST) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk & volatility, AQST or ANL? Aquestive Therapeutics has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.77, indicating that its stock price is 177% less volatile than the S&P 500. Does the MarketBeat Community favor AQST or ANL? Aquestive Therapeutics received 204 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 68.17% of users gave Aquestive Therapeutics an outperform vote. CompanyUnderperformOutperformAquestive TherapeuticsOutperform Votes21268.17% Underperform Votes9931.83% Adlai NortyeOutperform Votes8100.00% Underperform VotesNo Votes Is AQST or ANL more profitable? Adlai Nortye has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-59.75% N/A -33.96% Adlai Nortye N/A N/A N/A Do institutionals & insiders have more ownership in AQST or ANL? 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to AQST or ANL? In the previous week, Aquestive Therapeutics had 13 more articles in the media than Adlai Nortye. MarketBeat recorded 15 mentions for Aquestive Therapeutics and 2 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 1.25 beat Aquestive Therapeutics' score of 0.87 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Overall Sentiment Aquestive Therapeutics Positive Adlai Nortye Positive Do analysts rate AQST or ANL? Aquestive Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 212.50%. Adlai Nortye has a consensus target price of $9.00, suggesting a potential upside of 291.30%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Aquestive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Adlai Nortye 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, AQST or ANL? Aquestive Therapeutics has higher revenue and earnings than Adlai Nortye. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$58.90M5.45-$7.87M-$0.45-7.82Adlai Nortye$5M16.97-$104.87MN/AN/A SummaryAquestive Therapeutics beats Adlai Nortye on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.87M$6.70B$5.23B$9.28BDividend YieldN/A2.98%5.12%4.28%P/E RatioN/A10.5587.6917.27Price / Sales16.97199.001,168.45119.91Price / CashN/A57.1543.2337.82Price / BookN/A5.174.834.94Net Income-$104.87M$151.96M$120.76M$225.76M7 Day Performance7.48%3.11%2.49%3.92%1 Month Performance5.99%-4.17%17.55%1.71%1 Year Performance-74.59%7.50%28.51%15.79% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.9678 of 5 stars$2.20-4.3%$9.00+309.1%-74.6%$81.18M$5M0.00127Short Interest ↑Positive NewsGap DownAQSTAquestive Therapeutics2.1533 of 5 stars$3.59-1.6%$11.00+206.4%+76.0%$327.33M$58.90M-7.98160ETONEton Pharmaceuticals1.6804 of 5 stars$12.50-0.6%$15.00+20.0%+175.8%$325.64M$34.68M-56.8220SLRNAcelyrin2.765 of 5 stars$3.18+1.0%$11.75+269.5%-55.5%$319.04MN/A-1.29135Positive NewsBTMDbiote2.6094 of 5 stars$5.79-5.1%$9.11+57.3%+18.3%$314.61M$193.06M22.27194Short Interest ↑VYGRVoyager Therapeutics4.6451 of 5 stars$5.73-0.3%$17.00+196.7%-31.8%$313.01M$163.78M8.07100CGCCanopy Growth2.057 of 5 stars$2.87+1.4%$3.50+22.0%-45.3%$312.67M$280.50M-0.581,029Short Interest ↑Positive NewsTRVITrevi Therapeutics2.1993 of 5 stars$4.06+0.2%$9.31+129.4%+187.8%$312.08MN/A-9.2320Short Interest ↑SNDLSNDL2.9853 of 5 stars$1.85+2.8%$3.25+75.7%+18.2%$307.14M$911.22M-5.972,516News CoveragePROCProcaps Group1.6491 of 5 stars$2.64+5.2%N/A-29.1%$297.85M$414.10M5.085,500Short Interest ↓Gap UpCRVSCorvus Pharmaceuticals2.4841 of 5 stars$4.55-8.8%$12.83+182.1%+188.2%$292.37MN/A-4.8930High Trading Volume Related Companies and Tools Related Companies Aquestive Therapeutics Alternatives Eton Pharmaceuticals Alternatives Acelyrin Alternatives biote Alternatives Voyager Therapeutics Alternatives Canopy Growth Alternatives Trevi Therapeutics Alternatives SNDL Alternatives Procaps Group Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANL) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
